| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2018NatCo...9.5429W |
| P356 | DOI | 10.1038/S41467-018-07881-9 |
| P932 | PMC publication ID | 6303321 |
| P698 | PubMed publication ID | 30575753 |
| P50 | author | So-Yon Lim | Q56474030 |
| Merlin L Robb | Q56871310 | ||
| Dan H. Barouch | Q60489346 | ||
| Mark G. Lewis | Q66732036 | ||
| Christa E Osuna | Q37366665 | ||
| Peter Abbink | Q47695590 | ||
| Nelson Michael | Q48165776 | ||
| P2093 | author name string | Romas Geleziunas | |
| James B Whitney | |||
| Alison Hill | |||
| Elsa Chen | |||
| Jessica L Kublin | |||
| Po-Ting Liu | |||
| Gyeol Yoon | |||
| Erica N Borducci | |||
| P2860 | cites work | Re-emergence of HIV after stopping therapy | Q59060012 |
| Limited durability of viral control following treated acute HIV infection | Q24804986 | ||
| Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection | Q28481938 | ||
| Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV | Q28551642 | ||
| Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1 | Q28655602 | ||
| Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy | Q29615992 | ||
| Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy | Q29615993 | ||
| Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection | Q29619738 | ||
| Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment | Q33782843 | ||
| Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys | Q34020988 | ||
| Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study | Q34629153 | ||
| Latency in human immunodeficiency virus type 1 infection: no easy answers | Q35044157 | ||
| Viremic relapse after HIV-1 remission in a perinatally infected child | Q35633017 | ||
| Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection | Q36066494 | ||
| Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection | Q36225040 | ||
| Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques | Q37171570 | ||
| High frequencies of resting CD4+ T cells containing integrated viral DNA are found in rhesus macaques during acute lentivirus infections | Q37194757 | ||
| Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys | Q37486401 | ||
| Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus | Q37586965 | ||
| Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. | Q41880147 | ||
| Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine | Q42274867 | ||
| HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. | Q45954015 | ||
| Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy | Q47960975 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 5429 | |
| P577 | publication date | 2018-12-21 | |
| P1433 | published in | Nature Communications | Q573880 |
| P1476 | title | Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy | |
| P478 | volume | 9 |
| Q92407940 | Arsenic Trioxide Impacts Viral Latency and Delays Viral Rebound after Termination of ART in Chronically SIV-Infected Macaques |
| Q90707628 | Curing HIV: Seeking to Target and Clear Persistent Infection |
| Q96576975 | HIV and antiretroviral therapy-related fat alterations |
| Q90038614 | Immunotherapy with DNA vaccine and live attenuated rubella/SIV gag vectors plus early ART can prevent SIVmac251 viral rebound in acutely infected rhesus macaques |
| Q91722858 | Longitudinal bioluminescent imaging of HIV-1 infection during antiretroviral therapy and treatment interruption in humanized mice |
| Q83225592 | Predictors of SIV recrudescence following antiretroviral treatment interruption |
| Q92480393 | Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity |
| Q90263664 | The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques |
Search more.